Latest Content

The update introduces a 250 kHz scan speed for OCT Angiography combined with enhanced TruTrack Active Eye Tracking, as well as new multimodal imaging capabilities, including the Green Autofluorescence Module.

Epion completes phase 3 follow-up for EpiSmart epi-on corneal cross-linking in keratoconus, advancing toward FDA NDA and a less painful alternative.

A case study that highlights the importance of multimodal imaging in practice for early identification of rare inherited retinal dystrophies.

Oculis launches a genotype-guided dry eye trial testing licaminlimab eye drops, targeting TNFR1 patients and measuring Day 29 ocular discomfort improvement.

The lens is scheduled to become available in the US in fall 2026.

The study, conducted through the OHDSI network, analyzed records from 227,971 new users of semaglutide.

Daniel C. Brocks, MD, BostonSight chief medical officer, discusses a few of the company's studies, the patients they serve, and what the broader eye care community may be missing.

The free web-based tool guides eye care providers through evidence-based amblyopia diagnosis and treatment without requiring pediatric subspecialty training.

LENZ Therapeutics licenses FDA-approved presbyopia drop to Everest Medicines for Greater China; NDA under review by NMPA with approval anticipated in Q1 2027.

Clark Chang, OD, MSA, MSc, FAAO, FSLS, and Susan Gromacki, OD, MS, FAAO, FSLS, provide insights into their expertise.

The strength of our referral relationships defines the quality of our patients' eye health journey.

Mile Brujic, OD, FAAO, details his experience in manufacturing his new ScleralEase device and what other ODs can learn from his experience.

Researchers from Yale School of Medicine weigh in on what everyday clinicians can take away from their findings.